Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer
Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, s...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (202 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993553545304498 |
---|---|
ctrlnum |
(CKB)5600000000483127 (oapen)https://directory.doabooks.org/handle/20.500.12854/91177 (EXLCZ)995600000000483127 |
collection |
bib_alma |
record_format |
marc |
spelling |
Ferroni, Patrizia edt Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (202 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed. English Medicine bicssc Oncology bicssc multiple myeloma venous thromboembolism risk assessment models thromboprophylaxis direct oral anticoagulants cancer-associated venous thromboembolism thrombosis pulmonary embolism neoplasms anticoagulants coumarins low molecular weight heparins cancer endogenous heparin heparanase heparan sulfate hospice palliative care units low molecular weight heparin deep vein thrombosis cancer associated thrombosis VTE malignancy direct oral anticoagulant pancreatic cancer low-molecular weight heparin survival coagulation activation locally advanced breast cancer prognostic model pCR treatment prophylaxis DOAC simultaneous care integrated care lymphoma Non-Hodgkin lymphoma Hodgkin lymphoma risk factors molecular subtype arterial thrombosis ALK ROS1 KRAS chemotherapy low-molecular-weight heparin (LMWH) VKA UFH DOACs 3-0365-4707-X 3-0365-4708-8 Roselli, Mario edt Guadagni, Fiorella edt Ferroni, Patrizia oth Roselli, Mario oth Guadagni, Fiorella oth |
language |
English |
format |
eBook |
author2 |
Roselli, Mario Guadagni, Fiorella Ferroni, Patrizia Roselli, Mario Guadagni, Fiorella |
author_facet |
Roselli, Mario Guadagni, Fiorella Ferroni, Patrizia Roselli, Mario Guadagni, Fiorella |
author2_variant |
p f pf m r mr f g fg |
author2_role |
HerausgeberIn HerausgeberIn Sonstige Sonstige Sonstige |
title |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
spellingShingle |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
title_full |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
title_fullStr |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
title_full_unstemmed |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
title_auth |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
title_new |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
title_sort |
risk prediction and new prophylaxis strategies for thromboembolism in cancer |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (202 p.) |
isbn |
3-0365-4707-X 3-0365-4708-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT ferronipatrizia riskpredictionandnewprophylaxisstrategiesforthromboembolismincancer AT rosellimario riskpredictionandnewprophylaxisstrategiesforthromboembolismincancer AT guadagnifiorella riskpredictionandnewprophylaxisstrategiesforthromboembolismincancer |
status_str |
n |
ids_txt_mv |
(CKB)5600000000483127 (oapen)https://directory.doabooks.org/handle/20.500.12854/91177 (EXLCZ)995600000000483127 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1796649042661343232 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04306nam-a2200949z--4500</leader><controlfield tag="001">993553545304498</controlfield><controlfield tag="005">20231214132936.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202208s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5600000000483127</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/91177</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995600000000483127</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ferroni, Patrizia</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (202 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multiple myeloma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">venous thromboembolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk assessment models</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thromboprophylaxis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">direct oral anticoagulants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer-associated venous thromboembolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thrombosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary embolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticoagulants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coumarins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low molecular weight heparins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">endogenous heparin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heparanase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heparan sulfate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hospice</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">palliative care units</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low molecular weight heparin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">deep vein thrombosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer associated thrombosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VTE</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">malignancy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">direct oral anticoagulant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low-molecular weight heparin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coagulation activation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">locally advanced breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pCR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prophylaxis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DOAC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">simultaneous care</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">integrated care</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lymphoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Non-Hodgkin lymphoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hodgkin lymphoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular subtype</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">arterial thrombosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ALK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ROS1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">KRAS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low-molecular-weight heparin (LMWH)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VKA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">UFH</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DOACs</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4707-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4708-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roselli, Mario</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guadagni, Fiorella</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferroni, Patrizia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roselli, Mario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guadagni, Fiorella</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:36:47 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-08-13 21:17:26 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5339473400004498&Force_direct=true</subfield><subfield code="Z">5339473400004498</subfield><subfield code="b">Available</subfield><subfield code="8">5339473400004498</subfield></datafield></record></collection> |